Structural Racism and Kidney Health: A Framework for Policy Reform in Chronic Kidney Disease Management

Chronic Kidney Disease (CKD) is not merely a medical condition but a social phenomenon deeply embedded within the structures of systemic racism. The disproportionate burden of CKD among racial minorities—particularly Black, Hispanic, and Indigenous populations—is not an accident of biology but the predictable outcome of policies and practices that have systematically denied these communities access to the resources necessary for kidney health.

From redlined neighborhoods to biased clinical algorithms, structural racism operates at every level of the healthcare system to produce and perpetuate disparities in CKD outcomes. This article presents a framework for understanding these mechanisms and advocates for policy reforms that address the root causes of racial inequities in kidney health.

The historical roots of racial disparities in CKD extend deep into the 20th century, when federal housing policies like the National Housing Act of 1934 explicitly excluded Black and Hispanic families from homeownership opportunities through redlining (Rothstein, 2017). These policies concentrated poverty and environmental hazards in minority neighborhoods, creating the geographic foundations for health disparities that persist today. The legacy of redlining manifests in the clustering of dialysis centers in wealthier, predominantly White areas while 'food deserts' and 'medication deserts' proliferate in low-income, minority communities. This spatial inequity in healthcare infrastructure ensures that even when minority patients seek care, they are often directed to lower-quality facilities or face longer travel times to reach nephrology specialists.

The modern healthcare system perpetuates these historical inequities through institutional practices that disproportionately harm racial minorities. One of the most egregious examples is the use of race-based eGFR (estimated glomerular filtration rate) calculations, which adjust kidney function estimates upward for Black patients, thereby delaying their eligibility for kidney transplants and specialized care (Eneanya et al., 2019). This practice, rooted in flawed 19th-century racial pseudoscience, has only recently been challenged and remains embedded in clinical guidelines. Similarly, the tiered structure of insurance coverage—where employer-sponsored plans often provide superior access to nephrologists compared to Medicaid or Medicare—disproportionately affects minority patients who are more likely to rely on public insurance due to systemic employment discrimination.

Policy discrimination extends beyond healthcare delivery to the very frameworks used to allocate resources. The Medicare End-Stage Renal Disease (ESRD) Program, established in 1972, provides comprehensive coverage for dialysis but excludes coverage for kidney transplants—a critical intervention that offers better survival rates and quality of life. This policy disproportionately affects Black and Hispanic patients, who are more likely to develop ESRD due to the factors outlined above. Additionally, the lack of universal healthcare coverage in the United States means that many minority patients delay seeking care for CKD until it reaches advanced stages, when treatment options are limited and outcomes are poor. The structural barriers to early intervention thus create a feedback loop where disparities in CKD outcomes are both a cause and consequence of systemic inequities.

Institutional practices within healthcare systems further entrench racial disparities in CKD. Implicit bias among healthcare providers leads to differential treatment recommendations, with Black patients less likely to be referred for kidney transplants or offered conservative management options (Sehgal, 2003). The underrepresentation of minority physicians and nephrologists—only 3% of practicing nephrologists are Black (AAMC, 2023)—compounds this bias, as patients are less likely to receive culturally competent care. Furthermore, the fragmentation of healthcare services—where primary care, nephrology, and social services operate in silos—disproportionately affects minority patients who often lack the resources to navigate these complex systems. The result is a healthcare system that is structurally incapable of addressing the needs of marginalized communities.

Addressing structural racism in CKD management requires a comprehensive policy reform framework that targets its manifestations at every level of the healthcare system. First, the elimination of race-based clinical algorithms—such as the eGFR race coefficient—must be prioritized, with race-neutral alternatives implemented immediately. Second, policies must ensure equitable access to preventive care through expanded Medicaid coverage, increased funding for community health centers, and mandatory inclusion of diverse populations in clinical trials. Third, structural reforms should address the geographic inequities in healthcare infrastructure by incentivizing the establishment of nephrology clinics and dialysis centers in underserved areas. Finally, anti-racism training must be mandated for all healthcare providers, and diversity in the medical workforce must be actively promoted to ensure culturally competent care.

Policy reform must be coupled with meaningful community engagement to ensure that interventions are responsive to the needs of affected populations. Community-based participatory research (CBPR) approaches, where affected communities are involved in the design and implementation of health interventions, have shown promise in improving CKD outcomes in minority populations. For example, programs like the 'Healthy Kidneys' initiative in Chicago have successfully reduced CKD progression in Black communities by combining culturally tailored education with access to fresh produce and exercise programs. These grassroots efforts demonstrate that when communities are empowered to take ownership of their health, disparities can be reduced. However, such programs require sustainable funding and institutional support to scale effectively.

The future of CKD policy must move beyond piecemeal reforms to address the structural foundations of racial inequities. This requires a paradigm shift in how we conceptualize kidney health, recognizing it as a product of social, economic, and environmental justice as much as medical care. Potential policy directions include universal healthcare coverage, reparative justice measures for historically marginalized communities, and the establishment of a federal CKD equity task force to monitor and address disparities. Additionally, the integration of environmental justice into CKD policy—such as regulations on industrial pollution and lead exposure—can address the environmental determinants of kidney disease. By centering racial equity in CKD policy, we can begin to dismantle the structures that have produced and perpetuated disparities for generations.

Structural racism is not an abstract concept but a tangible force that shapes every aspect of kidney health, from the neighborhoods where patients live to the clinical algorithms that determine their treatment. The racial disparities in Chronic Kidney Disease are not anomalies but the logical outcome of policies and practices that have systematically disadvantaged racial minorities for centuries. Addressing these disparities requires more than medical interventions; it demands a commitment to dismantling the structural inequities that produce them. By reforming healthcare policies, engaging affected communities, and centering racial equity in CKD management, we can begin to build a healthcare system that is not only more effective but also more just. The cost of inaction is not merely measured in dollars but in the lives of those who continue to suffer under the weight of systemic racism.